Clinical Trial Search

Primary: Pharmacokinetics (PK): Mean Time-Matched Difference in Placebo-Adjusted QTcF Interval With Time Matched Concentrations Between LY3039478 Capsule Formulation (Formulation…

Primary: Incidence of Safety and Reactogenicity Events: Adverse Events — 1; 4; 2; 4 Participants

Primary: Number of Participants With Adverse Events (AEs) — 3; 3; 15; 1 participants

Primary: Number of Participants With Dose-limiting Toxicities (DLT) After Administration of Enoblituzumab and Pembrolizumab or Retifanlimab — 1; 0; 0; 0 Participants

Primary: SCY-078 Breast Milk Concentrations. — 0; 37.64; 72.22; 43.85 ng/mL

Primary: Dose-limiting Toxicities During the First 4 Weeks of Treatment — 0 participants

Primary: Effect of RBT-1 on Plasma Ferritin Levels — 592.3; 538.8; 313.7; 308.2 Percent change from baseline

Primary: Number of Participants With LY3039478 Dose-Limiting Toxicities (DLTs) — 0; 0 Participants

Primary: WHO Anthropometric Measure of Weight-for-Age Z-Score — -0.32; -0.80; -1.59; -0.29 Z-scores

Primary: Part 1: Infectivity Rate Based on Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) From Day 1 PM Through Day 8 AM — 15 Participants

Primary: Number of Participants With Solicited Local and General Adverse Events (AEs) — 10; 5; 8; 5 Participants

Primary: Regional SUVR Value for 18F-MK-6240 — 1.27 SUVR

Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) — 66.7; 77.8; 50.0; 0 percentage of participants

Primary: Part 1 - Percentage of Participants With an Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Liver Enzyme Elevation Greater Than Three Times the Upper…

Primary: Number of Participants With Adverse Events — 5; 9; 10; 8 Participants